Announced details
Early detection, diagnosis and prevention of Alzheimer's disease and dementia; municipal health screenings; primary care; telemedicine
FRONTEO will participate in the AMED dementia research and development project led by Oita University and Beppu City and will be responsible for researching an early detection model using KIBIT. Capital and personnel relationships: not disclosed.
Oita University: located in Oita City. Beppu City: Beppu City, Oita Prefecture. AMED: Japan Agency for Medical Research and Development. Other details: not disclosed.
Beppu City (validation site)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Equation-driven AI KIBIT (KIBIT) |
| Counterparty | National University Corporation Oita University, Beppu City, Oita Prefecture, Japan Agency for Medical Research and Development (AMED) |
| Counterparty overview | Oita University: located in Oita City. Beppu City: Beppu City, Oita Prefecture. AMED: Japan Agency for Medical Research and Development. Other details: not disclosed. |
| Relationship with the Company | FRONTEO will participate in the AMED dementia research and development project led by Oita University and Beppu City and will be responsible for researching an early detection model using KIBIT. Capital and personnel relationships: not disclosed. |
| Launch date | September 2026 (scheduled; start of validation study) |
| Applicable area | Early detection, diagnosis and prevention of Alzheimer's disease and dementia; municipal health screenings; primary care; telemedicine |
| Location | Beppu City (validation site) |
| Location scale | 800 Beppu residents aged 50 to under 90 |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To facilitate the early detection and prevention of Alzheimer's disease, support and streamline diagnosis, address the shortage of specialists, promote telemedicine, contain medical and long-term care insurance costs, and extend healthy life expectancy.